---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Definition and etiology"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Definition and etiology. Topics: Disease definition: nondiabetic kidney disease in a person with two APOL1 risk variants; Terminology: APOL1 kidney disease at the 2024 KDIGO Controversies Conference, and ICD-10-CM codes; Genetic cause: G1 and G2 variants with a recessive two-risk-allele genotype; Evolutionary origin: positive selection for resistance to African trypanosomiasis; 6 further topics. 10 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Disease definition: nondiabetic kidney disease in a person with two APOL1 risk variants

> “AMKD is diagnosed when an individual with a high-risk APOL1 genotype develops nondiabetic kidney disease. There is no established glomerular filtration rate (GFR) cutoff to diagnose AMKD. Proteinuria (urine albumin to creatinine ratio >30 mg/g) is often present but is not a requirement for the diagnosis of AMKD.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “APOL1-associated nephropathy reflects a spectrum of kidney diseases caused by APOL1 risk variants. It can be superimposed on other forms of kidney disease, but often, it presents as glomerulosclerosis with accompanying tubulointerstitial and vascular changes.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “AMKD is a rapidly progressing, proteinuric kidney disease caused by two variants in the APOL1 gene. It occurs in people of African ancestry.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.2.1.1-2"></a>

### Terminology: APOL1 kidney disease at the 2024 KDIGO Controversies Conference, and ICD-10-CM codes

> “The terms APOL1-mediated or -associated kidney disease lacked universal support largely because APOL1 high-risk genotypes are probabilistic—not deterministic—risk factors for developing kidney disease, and most people with high-risk APOL1 genotypes do not develop clinically apparent kidney disease.”
> “The term APOL1 kidney disease received the highest support for describing kidney pathologies associated with the G1 and G2 variants.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “New International Classification of Disease-10th Edition-Clinical Modification codes for APOL1-mediated kidney disease (AMKD) and family history of AMKD in the United States provide great hope to the millions of people with recent African ancestry and chronic kidney disease worldwide. In the past, vague diagnosis codes forced misclassification of many such patients, especially nondiabetic persons of African ancestry.”

Source: [Freedman et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41577386/)

<a id="topic-2.2.1.1-3"></a>

### Genetic cause: G1 and G2 variants with a recessive two-risk-allele genotype

> “In people of African ancestry, 2 apolipoprotein L1 gene (APOL1) variants have been identified as causing increased risk of progressive chronic kidney disease (CKD) compared with non–high-risk APOL1 variants.”
> “The risk variants, labelled G1 (2 amino acid substitutions) and G2 (2 deletions), confer resistance to infection from certain subspecies of the trypanosome parasite. Combinations of 2 risk variants (G1/G1, G2/G2, or G1/G2) are referred to as high-risk genotypes for the development or progression of CKD, and they are associated with a spectrum of kidney diseases of both continuous and categorical disease phenotypes (Figure 1).”
> “There is emerging evidence that a single risk allele (G1/G0 or G2/G0) may also confer risk.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “The risk of kidney disease associated with the APOL1 G1 and G2 alleles follows a recessive inheritance pattern. Individuals who are heterozygous for a G1 or G2 variant (G1/G0 or G2/G0) are resistant to African sleeping sickness but do not have increased risk of kidney disease.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “Genetic risk factors include two independent coding variants in the APOL1 gene, G1 and G2, which are found almost exclusively in people with recent West sub-Saharan African ancestry.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.1.1-4"></a>

### Evolutionary origin: positive selection for resistance to African trypanosomiasis

> “The two APOL1 variants are common in African chromosomes but absent from European chromosomes and both reside within haplotypes that harbor signatures of positive selection. ApoL1 is a serum factor that lyses trypanosomes. In vitro assays revealed that only the kidney disease-associated ApoL1 variants lysed Trypanosoma brucei rhodesiense.”

Source: [Genovese et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2980843/)

> “The G1 and G2 variants of the APOL1 gene restored immune protection against the novel T brucei strains and underwent positive selection in West Africa.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “These high-risk APOL1 variants are hypothesized to have evolved more than 10,000 years ago and rose to a high frequency in Africa because they provided protection against lethal African sleeping sickness due to Trypanosoma brucei rhodesiense and gambiense infections.”

Source: [Gbadegesin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11735277/)

<a id="topic-2.2.1.1-5"></a>

### Phenotype spectrum: FSGS, hypertension-attributed kidney disease, HIVAN, COVAN, lupus nephritis, and sickle cell nephropathy

> “APOL1 high-risk genotypes have been associated with several kidney diseases, including FSGS, HIV-associated nephropathy, hypertension-attributed ESKD, lupus nephritis, and sickle cell disease nephropathy.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “As discussed above, high-risk APOL1 genotypes have been associated with a spectrum of kidney disease phenotypes: vascular disease (hypertension-attributed kidney failure), diseases of the podocyte, and infectious etiologies such as HIV- and COVID-associated nephropathy.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “APOL1 risk variants increase the risk of hypertension-attributed ESKD (H-ESKD; 7- to 11-fold), FSGS (17-fold), HIV-associated nephropathy (HIVAN; 29- to 89-fold), nondiabetic CKD (2- to 4-fold), and other kidney disease manifestations. APOL1 does not appear to affect risk for developing IgA nephropathy or diabetic nephropathy (but does have some influence on progression in patients with diabetes and proteinuric kidney disease).”

Source: [Friedman and Pollak (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7863644/)

> “Kidney diseases in the spectrum include FSGS with and without nephrotic-range proteinuria, HIV-associated nephropathy (HIVAN), interferon-associated FSGS, severe lupus nephritis (LN), sickle cell nephropathy, and solidified glomerulosclerosis with low-level proteinuria.”

Source: [Freedman et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6200346/)

<a id="topic-2.2.1.1-6"></a>

### FSGS, hypertension-attributed ESKD, and HIVAN: odds ratios in the case-control studies

> “Here we show that in African-Americans, focal segmental glomerulosclerosis (FSGS) and hypertension-attributed end-stage kidney disease (H-ESKD) are associated with two independent sequence variants in the APOL1 gene on chromosome 22 [FSGS odds ratio = 10.5 (95% CI 6.0–18.4); H-ESKD odds ratio = 7.3 (95% CI 5.6–9.5)].”

Source: [Genovese et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2980843/)

> “In a recessive model, APOL1 variants conferred seventeenfold higher odds (95% CI 11 to 26) for focal segmental glomerulosclerosis (FSGS) and twenty-nine-fold higher odds (95% CI 13 to 68) for HIV-associated nephropathy (HIVAN).”

Source: [Kopp et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3231787/)

<a id="topic-2.2.1.1-7"></a>

### COVID-19-associated collapsing glomerulopathy (COVAN)

> “This case series included six Black patients with COVID-19 (four men, two women), mean age 55 years.”
> “All six patients had an APOL1 high-risk genotype. Five patients needed dialysis (two of whom died); one partially recovered without dialysis.”

Source: [Wu et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7460910/)

> “The 23 patients with COVID-19–associated collapsing glomerulopathy were median age 57 years (range, 35–72), included 16 men, and were predominantly (91%) Black.”
> “Among 17 patients genotyped, 16 (94%) were high-risk APOL1.”

Source: [Kudose et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8806099/)

<a id="topic-2.2.1.1-8"></a>

### Lupus nephritis: APOL1 and lupus nephritis-attributed ESKD

> “The G1/G2 risk alleles were strongly associated with SLE-ESRD, with 25% of cases and 12% of controls having 2 nephropathy alleles”
> “The age-, sex-, and admixture-adjusted population attributable risk for ESRD among patients with G1/G2 polymorphisms was 0.26, compared to 0.003 among European American patients. The mean time from SLE diagnosis to ESRD development was ~2 years earlier among individuals with APOL1 risk genotypes (P = 0.01).”

Source: [Freedman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4002759/)

<a id="topic-2.2.1.1-9"></a>

### Second hits and modifiers: interferon, viral infection, and the p.N264K variant

> “The two-hit hypothesis suggests that a high-risk APOL1 genotype could act as a first hit, but a second hit, such as modifier genes, HIV infection, SLE, or other comorbidity, may be required to initiate nephropathy.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “Even among individuals with a high-risk genotype, having 2 APOL1 risk alleles does not necessarily lead to development of CKD.”
> “Nongenetic second hits resulting in glomerular disease include high interferon states, viral infections (HIV and COVID-19), exposure to alpha, beta, or gamma interferon, and APOL1 overexpression”
> “Expression of APOL1 is regulated by cytokines (mostly by interferon), inflammation, hypoxia/ischemia, viruses, and nucleic acids.”
> “The APOL1 p.N264K variant was recently found to genetically and almost completely negate the effect of G2 risk alleles to levels comparable to G0, and this observation has been replicated in subsequent studies, making APOL1 p.N264K the most robust genetic modifier of APOL1 G2 to date.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Using human kidney organoids, primary endothelial cells, and patient samples, we demonstrate that IFN-γ induces pyroptotic angiopathy in combination with APOL1 expression.”

Source: [Juliar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11216883/)

<a id="topic-2.2.1.1-10"></a>

### Unpredictability of disease among genotype carriers

> “Despite the strong association between having a high-risk genotype and increased risk of kidney disease, it is not possible to predict which individuals with a high-risk genotype will develop CKD, idiopathic FSGS, hypertension-attributed kidney disease, HIV-1–associated nephropathy (HIVAN), or earlier failure of a kidney transplant from a donor with an APOL1 high-risk genotype.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Although the majority of people with a high-risk APOL1 genotype will not develop CKD, we cannot currently predict who will be affected.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
